Tag Archives: Ultragenyx

October, 2018

26 October
Ultragenyx Announces Negative Topline Results from Phase 3 Study of UX007 in Patients with Glut1 DS with Disabling Movement Disorders

NOVATO, Calif., Oct. 26, 2018 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced its Phase 3 study of UX007 in patients with glucose transporter type-1 deficiency syndrome (Glut1 DS) experiencing disabling …
Share

18 May
Crysvita Meets Primary Endpoint in Phase 3 Trial in Children with X-Linked Hypophosphatemia

NOVATO, Calif. and TOKYO and LONDON, May 17, 2018 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, Kyowa Hakko Kirin Co. Ltd(Kyowa Hakko Kirin), and Kyowa Kirin International PLC (Kyowa Kirin International) today announced that the Phase 3 study of Crysvita® …
Share

18 April
FDA Approves Crysvita, The First Therapy for X-Linked Hypophosphatemia, A Rare Inherited Form of Rickets

NOVATO, Calif. and TOKYO and LONDON, April 17, 2018 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, Kyowa Hakko Kirin Co. Ltd(Kyowa Hakko Kirin), and Kyowa Kirin International PLC (Kyowa Kirin International) today announced that the U.S. Food and Drug Administration (FDA) has approved Crysvita® (burosumab-twza) for …
Share

16 November
FDA Approves Ultragenyx’s Mepsevii for Treatment of a Rare, Genetic Disease

NOVATO, Calif., Nov. 15, 2017 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved MEPSEVII™ (vestronidase alfa), the first medicine approved for the treatment of …
Share

19 April
Ultragenyx Announces Positive Late-Stage Results for its X-Linked Hypophosphatemia Drug

NOVATO, Calif., LONDON and TOKYO, April 18, 2017 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin) and Kyowa Kirin International PLC, a wholly owned subsidiary of Kyowa Hakko Kirin, today announced positive 24-week data from the randomized, double-blind, placebo-controlled Phase 3 study of …
Share

8 June
Ultragenyx and Takeda Partner for Development Treatments for Rare Genetic Diseases

NOVATO, Calif. and OSAKA, Japan, June 07, 2016 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare genetic diseases, and Takeda Pharmaceutical Company Limited (TSE: 4502), today announced a strategic partnership to develop and commercialize therapies to treat …
Share

30 October
Ultragenyx and Arcturus Enter Potential $1.57 Billion RNA Collaboration

NOVATO, Calif., Oct. 29, 2015 /PRNewswire/ — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, and Arcturus Therapeutics, Inc., a leading RNA medicines company, today announced that they have entered into a research collaboration and license agreement to discover …
Share